mva-bn-cv301
Vaccineexperimental
Clinical trial activity
2 trials · 5 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
2
Phase 3
0
Phase 4
0
Earliest trial started Jun 26, 2018 (NCT03547999)
Timeline
Indications
Mechanism of action
- Tumor antigensImmunity, active
immunity, active - tumor antigens
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT04574583 | Phase 1/Phase 2 (Phase 2) | Nov 24, 2020 | National Cancer Institute (NCI) |
| NCT03547999 | Phase 2 | Jun 26, 2018 | Bavarian Nordic, Bristol-Myers Squibb, Hoosier Cancer Research Network, Rutgers University |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (5)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Bavarian Nordic | For profit | 1 | 0 | 1 | 2018 |
| Bristol-Myers Squibb | For profit | 1 | 0 | 1 | 2018 |
| Hoosier Cancer Research Network | Academic/Hospital | 1 | 1 | 1 | 2018 |
| National Cancer Institute (NCI) | Government | 1 | 1 | 1 | 2020 |
| Rutgers University | Academic/Hospital | 1 | 0 | 1 | 2018 |
5 organizations
Page 1 / 1